News

Telix Cleared to Commence Renal Cancer Imaging Study in Japan

Melbourne (Australia) and Kyoto (Japan) – 30 August 2019. Telix Pharmaceuticals Limited today announced the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-C

MELBOURNE (Australia) and KYOTO (Japan) – Aug. 30, 2019

Telix Pharmaceuticals Limited today announced the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in Japan. The Japanese Pharmaceutical and Medical Devices Agency (PMDA) has completed review of the proposed clinical trial and Telix is now permitted to proceed with the study. This study is the first of its kind in Japan.

To read the full media release click here.